Compare CASH & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | PVLA |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1996 | 2013 |
| Metric | CASH | PVLA |
|---|---|---|
| Price | $78.48 | $150.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $107.50 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 181.5K | 158.2K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | N/A | ★ 52.62 |
| EPS | ★ 6.29 | N/A |
| Revenue | ★ $839,894,000.00 | $42,810,000.00 |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $6.02 | $104,350.18 |
| P/E Ratio | $12.58 | ★ N/A |
| Revenue Growth | 11.29 | ★ 65.28 |
| 52 Week Low | $65.93 | $53.30 |
| 52 Week High | $101.26 | $161.38 |
| Indicator | CASH | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 50.00 |
| Support Level | $76.80 | $135.68 |
| Resistance Level | $85.41 | $158.29 |
| Average True Range (ATR) | 1.55 | 6.90 |
| MACD | -0.23 | -0.31 |
| Stochastic Oscillator | 8.10 | 63.65 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.